-
Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production
- Back
Metadata
Document Title
Glutaraldehyde erythropoietin protects kidney in ischaemia/reperfusion injury without increasing red blood cell production
Author
Chattong S, Tanamai J, Kiatsomchai P, Nakatsu M, Sereemaspun A, Pimpha N, Praditpornsilpa K, Rojanathanes R, Sethpakadee A, Tungsanga K, Eiam-Ong S, Manotham K
Name from Authors Collection
Affiliations
Chulalongkorn University; Chulalongkorn University; National Science & Technology Development Agency - Thailand; National Nanotechnology Center (NANOTEC); Chulalongkorn University; Chulalongkorn University; National Center for Global Health & Medicine - Japan
Type
Article
Source Title
BRITISH JOURNAL OF PHARMACOLOGY
ISSN
0007-1188
Year
2013
Volume
168
Issue
1
Page
189-199
Open Access
Green Published
Publisher
WILEY
DOI
10.1111/j.1476-5381.2012.02123.x
Format
Abstract
Background and Purpose Recombinant human erythropoietin (rHuEPO) is currently the mainstay of renal anaemia treatment. Recently, rHuEPO has been shown to provide pleiotrophic tissue protection in various pathological conditions. However, the benefits of rHuEPO beyond anaemia treatment are limited because it increases red blood cell mass. Carbamylated erythropoietin (CEPO) is the first rHuEPO derivative that lacks erythropoietic activity but retains tissue protection properties. Since carbamylation targets lysine residues on rHuEPo, we hypothesized that targeted lysine modifications of rHuEPO may result in a novel non-erythropoietic erythropoietin. Experimental Approach rHuEPO was subjected to various targeted lysine modifications. In vitro cytoprotection and apoptosis were evaluated using P19 and HEK293 cells. In vivo erythropoiesis was performed by administering the derivatives to animals for 2 weeks. Renoprotection was tested on an ischaemia/reperfusion (I/R) model. Key Results We synthesized a novel derivative, a glutaraldehyde erythropoietin (GEPO). This construct abolished in vivo erythropoiesis. Biochemical characterization showed that GEPO was more electrostatically negative than rHuEPO. Immunoprecipitation experiments revealed that GEPO bound to the IL3RB/EPOR heterotrimeric receptor and ameliorated cellular apoptosis via the activation of Bcl-2. Notably, Bcl-2 activation was suppressed by the JAK2 inhibitor, tyrphostin AG490. In vivo experiments showed that GEPO also ameliorated kidney damage due to I/R injury both functionally and histologically. Conclusions and Implications Herein, we describe a novel lysine-modified rHuEPO, glutaradehyde-EPO (GEPO), obtained from a simple reaction. This derivative has no erythropoietic properties but retains cell-protective characteristics both in vitro and in vivo, with promise for future use as an adjunctive treatment of kidney disease.
Keyword
Apoptosis | Bcl-2 | carbamylated | EPO | erythropoietin | glutaraldehyde erythropoietin | ischaemia | JAK | kidney injury | non-erythropoietic | reperfusion
Funding Sponsor
Thailand Research Fund (TRF); Department of Medical Services of Thailand; Japan International Cooperation Agency
License
Copyright
Rights
Authors
Publication Source
WOS